血清miR-326与治疗相关性血液系统恶性肿瘤患者化疗敏感性和预后的关系  

Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy

作　　者：陈哲[1] 张灵[1] 刘洁[1] 王霞 张斌[2] 高炳华[1] CHEN Zhe;ZHANG Ling;LIU Jie;WANG Xia;ZHANG Bin;GAO Binghua(Department of Hematology,the First Affiliated Hospital of Hebei North University,Zhangjiakou 075000,Hebei,China;Department of Clinical Laboratory,the First Affiliated Hospital of Hebei North University,Zhangjiakou 075000,Hebei,China)

机构地区：[1]河北北方学院附属第一医院血液科,河北张家口075000 [2]河北北方学院附属第一医院检验科,河北张家口075000

出　　处：《检验医学》2023年第3期251-256,共6页Laboratory Medicine

基　　金：2021年度河北省医学科学研究课题(20210427)。

摘　　要：目的探究血清微小RNA-326(miR-326)水平与治疗相关性血液系统恶性肿瘤患者化疗敏感性和预后的关系。方法选取2012年1月—2021年1月河北北方学院附属第一医院收治的50例治疗相关性血液系统恶性肿瘤患者(研究组),以同期40例无原发实体瘤的血液系统恶性肿瘤患者为对照组。采用实时荧光定量聚合酶链反应(RT-qPCR)检测所有患者血清miR-326相对表达量。研究组入院后均接受化疗,根据肿瘤评估情况分为化疗有效组和化疗无效组,比较2个组化疗前后血清miR-326相对表达量。采用Spearman相关分析评估血清miR-326相对表达量与治疗相关性血液系统恶性肿瘤患者化疗敏感性的相关性。对研究组患者进行随访,根据随访终点事件(全因死亡)将研究组患者分为存活组和死亡组,收集2个组患者的临床资料,采用Logistic回归分析评估治疗相关性血液系统恶性肿瘤患者预后的影响因素。采用受试者工作特征(ROC)曲线评估血清miR-326预测治疗相关性血液系统恶性肿瘤患者预后的价值。结果研究组血清miR-326相对表达量低于对照组(P<0.001)。化疗有效组化疗后血清miR-326相对表达量高于化疗前(P<0.05);化疗无效组化疗前后血清miR-326相对表达量差异无统计学意义(P>0.05)。血清miR-326相对表达量与治疗相关性血液系统恶性肿瘤患者化疗敏感性呈正相关(r=0.641,P<0.05)。死亡组高血压、感染、凝血功能异常、再发肿瘤化疗周期(≥5个)、脏器功能损伤所占比例均高于存活组,血清miR-326相对表达量低于存活组(P<0.05)。感染、凝血功能异常、脏器功能损伤、低血清miR-326相对表达量是治疗相关性血液系统恶性肿瘤患者预后不良的危险因素(P<0.05)。以0.44为最佳临界值,血清miR-326相对表达量预测治疗相关性血液系统恶性肿瘤患者预后的敏感性为86.80%,特异性为78.10%,曲线下面积为0.868。结论血清miR-326在治疗相Objective To investigate the relationship between serum microRNA-326(miR-326)and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy.Methods Totally,50 patients with treatment-related hematological malignancy in the First Affiliated Hospital of Hebei North University from January 2012 to January 2021 were enrolled(study group),and 40 patients with hematological malignancy without primary solid tumors during the same period were enrolled as control group.Serum miR-326 levels were determined by real-time fluorescence quantitative polymerase chain reaction(RT-qPCR).Study group received chemotherapy after admission,and they were classified into chemotherapy effective and chemotherapy ineffective groups according to the tumor assessment results.Serum miR-326 levels before and after chemotherapy were compared between the 2 groups,and the correlation between serum miR-326 levels and chemotherapy sensitivity in patients with treatment-related hematological malignancy was analyzed by Spearman correlation analysis.All the research subjects were followed up.The patients in study group were classified into survival and death groups according to the follow-up endpoint event(all-cause death),and the clinical data of the patients in the both groups were collected to analyze the factors influencing the prognosis of patients with treatment-related hematological malignancy using Logistic regression analysis.Receiver operating characteristic(ROC)curve was used to assess the effect of serum miR-326 on prognostic predictive value in patients with treatment-related hematological malignancy.Results Serum miR-326 level in study group was lower than that in control group(P<0.001).Serum miR-326 levels were higher in chemotherapy effective group after chemotherapy compared with those before chemotherapy(P<0.05),and the difference between serum miR-326 levels before and after chemotherapy in chemotherapy ineffective group was not statistically significant(P>0.05).Serum miR-326 levels were posit

关 键 词：微小RNA-326 治疗相关性血液系统恶性肿瘤 化疗 敏感性 预后 

分 类 号：R393[医药卫生—基础医学]